our Premium Content: News alerts, weekly reports and conference planners

GENE:

MIR675 (MicroRNA 675)

News alerts, weekly reports and conference planners

11d

Integrating traditional omics and AI-driven approaches for discovery and validation of novel MicroRNA biomarkers and therapeutic targets in thyroid cancer. (PubMed, Front Pharmacol)

This integrated framework successfully identified has-miR-6756-5p as both a diagnostic biomarker and therapeutic target, demonstrating how traditional experimental validation coupled with computational prediction enhances translational potential. The multi-scale approach spanning bulk transcriptomics, AI-driven biomarker selection, single-cell characterization, and functional validation represents an effective paradigm for developing clinically relevant cancer biomarkers and therapeutic targets.

11 days ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TGM2 (Transglutaminase 2) • ITM2A (Integral Membrane Protein 2A) • MIR675 (MicroRNA 675)

2ms

A novel super-enhancer-driven lncRNA LINC00973 governs head and neck squamous cell carcinoma progression through EN2. (PubMed, Cell Death Dis)

Clinically, the abundance of LINC00973, miR-6756-3p, EN2, and NOTCH1 in HNSCC samples was correlated and significantly associated with patients' survival. Collectively, our findings revealed a hitherto uncharacterized SE-driven LINC00973-miR-6756-3p-EN2 regulatory axis to facilitate HNSCC progression and highlighted LINC00973 as a promising prognostic biomarker and therapeutic target with considerable translational potential.

2 months ago

Journal

NOTCH1 (Notch 1) • EP300 (E1A binding protein p300) • BRD4 (Bromodomain Containing 4) • FOSL1 (FOS Like 1) • MIR675 (MicroRNA 675)

4ms

Integrated in-silico and in-vitro analysis of lncRNA H19/miRNA-675/p53 in OSCC: Structural characterization and molecular docking insights. (PubMed, Diagn Pathol)

The specificity of H19 expression in OSCC compared to normal presents an attractive target for cancer-specific therapies, minimizing the risk of off-target effects.

4 months ago

Preclinical • Journal

TP53 (Tumor protein P53) • H19 (H19 Imprinted Maternally Expressed Transcript) • MIR675 (MicroRNA 675)

4ms

lncRNA PAX8-AS1 suppresses cervical cancer development by regulating miR-675-3p/DCN axis. (PubMed, Int J Biol Markers)

PAX8-AS1 suppressed the CC cell invasion, migration, and proliferation by targeting miR-675-3p/DCN axis.ConclusionIn summary, PAX8-AS1 was related to tumor progression and inhibited CC development. As a potential biomarker, PAX8-AS1 impeded CC cell invasion, migration, and proliferation by regulating the axis of miR-675-3p/DCN.

4 months ago

Journal

PAX8 (Paired box 8) • MIR675 (MicroRNA 675) • PAX8-AS1 (PAX8 Antisense RNA 1)

5ms

IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF MICRORNAS REGULATING HTERT. (PubMed, Exp Oncol)

The current study provided a detailed procedure for identifying and verifying miRNAs against mRNAs, as well as highlighting the differential regulation of hTERT by specific miRNAs. It demonstrated that miRNA inhibition can modulate hTERT expression and cell proliferation, with potential implications for targeted cancer therapies. The strategy used in this study could also be applied to other genes for screening potential miRNAs.

5 months ago

Journal

TERT (Telomerase Reverse Transcriptase) • MIR675 (MicroRNA 675)

5ms

The functional role of exosomal miRNA-675-3p derived from patients with hepatocellular carcinoma. (PubMed, Transl Cancer Res)

miRNA-675-3p was upregulated in the serum of patients with HCC and exerted an oncogenic role in HCC cells via the targeting of downstream genes. These findings may constitute novel insights into the development of HCC, with miRNA-675-3p potentially serving as a biomarker for the diagnosis and treatment of patients with HCC.

5 months ago

Journal

MIR675 (MicroRNA 675)

6ms

The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer. (PubMed, Cancers (Basel))

Selected lncRNAs, including THOR and LINC01094, have also demonstrated significant prognostic value. Despite these advances, challenges persist, including inconsistent reporting, limited external validation, and a lack of replication by independent research groups.

6 months ago

Review • Journal

ERCC1 (Excision repair cross-complementation group 1) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • MIR21 (MicroRNA 21) • GAS6 (Growth arrest specific 6) • MIR211 (MicroRNA 211) • IGFBP3 (Insulin-like growth factor binding protein 3) • LINC01094 (Long Intergenic Non-Protein Coding RNA 1094) • MIR140 (MicroRNA 140) • MIR150 (MicroRNA 150) • MIR215 (MicroRNA 215) • MIR675 (MicroRNA 675) • SDC2 (Syndecan 2) • SEPTIN9 (Septin 9) • SNHG14 (Small Nucleolar RNA Host Gene 14) • ASB16-AS1 (ASB16 Antisense RNA 1)

6ms

miR-675-5p regulation of autophagy by TSC2 promotes cisplatin resistance in ovarian cancer. (PubMed, Cytotechnology)

Knocking down miR-675-5p can inhibit the mTOR signaling pathway and autophagy through TSC2, thereby reducing the DDP resistance of OC cells. This may provide a potential therapeutic target for OC.

6 months ago

Journal

TSC2 (TSC complex subunit 2) • MIR675 (MicroRNA 675)

cisplatin

7ms

Identification of key ferroptosis-related genes associated with the development of gastric cancer: Prognostic models, molecular mechanisms and potential treatment strategies. (PubMed, Oncol Lett)

Finally, using the Genomics of Drug Sensitivity in Cancer and Cancer Therapeutics Response Portal databases, potential drugs [(5Z)-7-oxozeaenol, selumetinib, RDEA119, AZ628, dabrafenib and trametinib] were identified based on the aforementioned seven key carcinogenic genes, focusing on those that targeted multiple genes. In conclusion, the present study identified 14 key ferroptosis-related genes, and seven key carcinogenic genes, which represent promising novel molecular targets for the prognosis and treatment of GC.

7 months ago

Journal

GJA1 (Gap Junction Protein Alpha 1) • AKR1C2 (Aldo-Keto Reductase Family 1 Member C2) • GABARAP (GABA Type A Receptor-Associated Protein) • MIR484 (MicroRNA 484) • NOX4 (NADPH Oxidase 4) • GABARAPL2 (GABA Type A Receptor Associated Protein Like 2) • MIR675 (MicroRNA 675) • NOX5 (NADPH Oxidase 5)

Mekinist (trametinib) • Tafinlar (dabrafenib) • Koselugo (selumetinib) • refametinib (BAY86-9766) • AZ 628

9ms

Identification of a JAK-STAT-miR155HG positive feedback loop in regulating natural killer (NK) cells proliferation and effector functions. (PubMed, Acta Pharm Sin B)

Collectively, we identify a miR155HG-mediated positive feedback loop of the JAK-STAT signaling. Our study will also provide a power target regarding miR155HG for improving NK cell generation and effector function in the field of NK cell adoptive transfer therapy against cancer, especially iPSC-derived NK cells.

9 months ago

Journal

STAT3 (Signal Transducer And Activator Of Transcription 3) • MIR155 (MicroRNA 155) • JAK3 (Janus Kinase 3) • MIR675 (MicroRNA 675)

9ms

Post-transcriptional regulation of H19 by m6A reader proteins: H19 stability versus miR-675 biogenesis. (PubMed, J Biol Chem)

Notably, a low CALN1/high H19 predicted a poor prognosis in GBM patients and was further exacerbated by a high METTL3 or HNRNPA2B1 but not IGF2BP2 transcript levels. Thus, we found that the H19 is a m6A modified transcript that is highly expressed in GBM, and the m6A reader proteins, IGF2BP2 and HNRNPA2B1, regulate H19 processing differently to promote glioma cell migration.

9 months ago

Journal

H19 (H19 Imprinted Maternally Expressed Transcript) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3) • MIR675 (MicroRNA 675)

11ms

An integrated multi-omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. (PubMed, Cancer Cytopathol)

These findings demonstrate that a multiomics biomarker approach with elevated PCF miRNAs with mutant KRAS, mutant GNAS, and serum CA19-9 may help in better detecting high-risk cysts for early clinical intervention.

11 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • CEACAM5 (CEA Cell Adhesion Molecule 5) • GNAS (GNAS Complex Locus) • CA 19-9 (Cancer antigen 19-9) • MIR675 (MicroRNA 675)